Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07595159
PHASE1

A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B

Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B. Ia involved a single ascending dose study where healthy participants were administered one dose of BW-20507 or placebo subcutaneously. Ib involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered with multiple doses of BW-20507 SC

Official title: A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Chinese Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity in Chinese Subjects With Chronic HBV Infection

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2024-06-24

Completion Date

2025-12-29

Last Updated

2026-06-26

Healthy Volunteers

Yes

Interventions

DRUG

Placebo

Solution for injection

DRUG

BW-20507

Solution for injection

Locations (4)

Argo Investigative Site

Beijing, Beijing Municipality, China

Argo Investigative Site

Chongqing, Chongqing Municipality, China

Argo Investigative Site

Guanzhou, Guangdong, China

Argo Investigative Site

Xuzhou, Jiangsu, China